Skip to main content

Table 1 AChR-ab titer, quantitative MG score, MGFA postintervention status, and concomitant drugs were assessed before and after the beginning with MMF treatment in 11 patients with AChR-ab positive MG.

From: Mycophenolate mofetil as second line immunosuppressant in myasthenia gravis - a long-term prospective open-label study

nr./sex age MGFA score medication before MM treatment (mg) reason for drug exchange MMF duration (months) Dose serum level (Qg/ml) concomitant treatment (mg) MGFA postintervention status during MMF change in status unchanged QMGS   AChR-ab (nmol/l)
           before after 1 before after 1
1. m/67 I PR 20
AZA 150
CH 360
gGT increase (15-fold) 46 2.0 g 2.26 none complete pharmacologic remission   0/24 0/24 21 17
2. m/52 I PR 40
AZA 150
CH 240
gGT increase (13-fold) 16 2.0 g 2.15 none minimal manifestations (mild ptosis) unchanged 3/24 3/24 3.6 10.4
3.m/59 I PR 20
CH 330
AZA 150
gGT increase (5-fold)
drug resistancy
7 2.0 g 2.43 PR (7.5) severe right ptosis CH (480) unchanged 3/24 3/24 5.0 2.3
     36 1.5 g (GI-problems) CH (20) IVIG10g/month minimal manifestation mild ptosis improvement   1/24   2.9
4.f/33 I PR 5
CH 270
AZA 150
nausea, vomiting 20 2.0 g 2.97 CH (180) incomplete pharmacol. Remission
after 20 mo generalization
exacerbation 1/24 5/24 0.21 0.44
5.m/77 IIa PR 20
AZA 150(13-fold)
CH 240
gGT increase
pancyopenia
20 2.0 g
1.0 g
n.a.
(flatulence)
none pharmacologic remission unchanged 0/24 0/24 1.6 6.7
6.f/64 IIa PR 20
AZA 200
CH 240
exacerbation 36 2.0 g
2.5 g
2.18 CH (150) complete pharmacologic remission improvement 7/24 3/24 31 39
7.f/20 IIb CH120
AZA 50
edema
(hand, feet)
20 1.5 g 0.72 CH (240) Complete pharmacol. remission improvement 6/24 4/24 43 22
8.f/43 IIIa PR 25
CH 240
AZA 150
lymphopenia 21 1.5 g 1.90 CH (240) Complete pharmacol. remission improvement 4/24 0/24 44 34
9.m/64 IIIa PR
CH
AZA
MTX
amylase/8
lipase increase
nausea, vomiting
2.0 g n.a.   CH (345) therapyresistancy unchanged 11/24 11/24 17 21
10.f/33 IIIb CH 330
AZA 50
recurrent 14
pancytopenia
persistent sympt.
1.0 g 0.50
0.5 g
  CH (270) incomplete pharmacol. remission
remission leucopenia
improvement 5/24 1/24 7.5 11.5
11.m/59 V PR 40
CH 540
AZA 150
persistant sympt. 26 2.0 g 3.05 PR (7.5)
CH (480)
incomplete pharmacol. remission improvement 11/24 4/24 200 24
  1. AchR-ab - acetylcholine receptor antibody, AZA - azathioprine, CH - choline esterase inhibitor, IVIG - intravenous immunoglobulins, MGFA - myasthenia gravis foundation association, MMF - mycophenolate mofetil, PR - prednisolone, QMGS, quantitative myasthenia gravis score for disease severity
  2. 1 i.e. at the end of the observation period